ASCO Annual Meeting

Overall survival rates for various cancers differed by race.

Knowledge gaps exist around the timing of pneumonitis onset in patients treated with checkpoint inhibitors.

A study from the 2021 ASCO Annual Meeting examined the effect that oral anticancer agent initiation may have on adherence rates in patients with multiple myeloma and chronic conditions.

A study from the 2021 ASCO Annual Meeting assessed the prevalence of oncology drug shortages and how they hinder care for patients with cancer.

A poster presentation at the 2021 ASCO Annual Meeting discussed survival trends among patients with chronic lymphocytic leukemia.

A community oncology practice implemented a team-based approach to utilizing biosimilars.

Results of the phase 3 OlympiA study evaluating olaparib as adjuvant therapy in high-risk early-stage breast cancer therapy were presented at the 2021 ASCO Annual Meeting.

A study highlighted at the 2021 ASCO Annual Meeting explored whether patients who received an influenza vaccine were at increased risk for immune-related adverse events from single-agent immune checkpoint inhibitors.

Results of the phase 3 RATIONALE 203 study were presented at the 2021 ASCO Annual Meeting.

Findings from the phase 3 RELATIVITY-047 trial were presented at the 2021 ASCO Annual Meeting.

The study, presented at the virtual ASCO20, showed significant clinical benefit for patients with endometrial cancer who were treated with cabozantinib and nivolumab.

The study’s authors examined the opportunity to decrease the overall cost of bortezomib by $300-400 million by switching patients to the generic version.

A systematic review of medical cannabis and cannabinoid use in oncology care demonstrated varied results. 

Targeted therapy osimertinib (Tagrisso) demonstrated significant improvements in disease-free survival in patients with localized non-small cell lung cancer (NSCLC) who were treated following surgery.

The study marks the first time that the drug has demonstrated benefit for front-line therapy in patients with this type of colorectal cancer.

An outpatient multiple myeloma clinic benefited substantially from employing a clinical pharmacist.

“Data collection is ongoing with additional analyses planned to look at patient and provider perception of COVID-19 impact on cancer care.”

SOLO-2 is the first phase 3 trial to provide overall survival (OS) data on maintenance PARP inhibitor therapy.

The study is the first of its kind on a national scale to show the benefit of Medicaid expansion on cancer mortality rates.

The findings, which were presented virtually in the 2020 ASCO Virtual Scientific Program, included the association between treatment with hydroxychloroquine plus azithromycin and increased risk of death.

The American Society of Clinical Oncology (ASCO) recently released a detailed guidance to oncology practices